{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:59:55Z","timestamp":1787673595535,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1038\/s41375-023-01879-z","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T10:03:12Z","timestamp":1679911392000},"page":"1028-1038","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Targeting a mitochondrial E3 ubiquitin ligase complex to overcome AML cell-intrinsic Venetoclax resistance"],"prefix":"10.1038","volume":"37","author":[{"given":"Fumihiko","family":"Nakao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoko","family":"Setoguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Semba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Imanaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Terasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manaka","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6684-9432","authenticated-orcid":false,"given":"Shigeki","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohta","family":"Miyawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikane","family":"Kikushige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4530-6460","authenticated-orcid":false,"given":"Takahiro","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"1879_CR1","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"1879_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392:593\u2013606.","journal-title":"Lancet"},{"key":"1879_CR3","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AMl in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1879_CR4","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","volume":"18","author":"H Dohner","year":"2021","unstructured":"Dohner H, Wei AH, Lowenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18:577\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"1879_CR5","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 201521:178\u201384.","journal-title":"Nat Med"},{"key":"1879_CR6","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of Venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106\u201317.","journal-title":"Cancer Discov"},{"key":"1879_CR7","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","volume":"24","author":"DA Pollyea","year":"2018","unstructured":"Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24:1859\u201366.","journal-title":"Nat Med"},{"key":"1879_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"1879_CR9","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1182\/blood.2020006785","volume":"138","author":"AW Roberts","year":"2021","unstructured":"Roberts AW, Wei AH, Huang DCS. BCL2 and MCL1 inhibitors for hematologic malignancies. Blood. 2021;138:1120\u201336.","journal-title":"Blood"},{"key":"1879_CR10","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137\u201345.","journal-title":"Blood"},{"key":"1879_CR11","doi-asserted-by":"publisher","first-page":"6902","DOI":"10.1021\/jm800669s","volume":"51","author":"CM Park","year":"2008","unstructured":"Park CM, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A, et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem. 2008;51:6902\u201315.","journal-title":"J Med Chem"},{"key":"1879_CR12","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med"},{"key":"1879_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","volume":"4","author":"R Pan","year":"2014","unstructured":"Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4:362\u201375.","journal-title":"Cancer Discov"},{"key":"1879_CR14","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41589-019-0306-6","volume":"15","author":"LD Walensky","year":"2019","unstructured":"Walensky LD. Targeting BAX to drug death directly. Nat Chem Biol. 2019;15:657\u201365.","journal-title":"Nat Chem Biol"},{"key":"1879_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","volume":"22","author":"ST Diepstraten","year":"2021","unstructured":"Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat Rev Cancer. 2021;22:45\u201364.","journal-title":"Nat Rev Cancer"},{"key":"1879_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","volume":"151","author":"TT Vo","year":"2012","unstructured":"Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012;151:344\u201355.","journal-title":"Cell"},{"key":"1879_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477\u201382.","journal-title":"Nature"},{"key":"1879_CR18","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.ccell.2018.01.012","volume":"33","author":"T Yamauchi","year":"2018","unstructured":"Yamauchi T, Masuda T, Canver MC, Seiler M, Semba Y, Shboul M, et al. Genome-wide CRISPR-Cas9 screen identifies leukemia-specific dependence on a Pre-mRNA metabolic pathway regulated by DCPS. Cancer Cell. 2018;33:386\u2013400 e385.","journal-title":"Cancer Cell"},{"key":"1879_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0843-6","volume":"16","author":"W Li","year":"2015","unstructured":"Li W, Koster J, Xu H, Chen CH, Xiao T, Liu JS, et al. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol. 2015;16:281.","journal-title":"Genome Biol"},{"key":"1879_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","volume":"36","author":"R Gui\u00e8ze","year":"2019","unstructured":"Gui\u00e8ze R, Liu VM, Rosebrock D, Jourdain AA, Hern\u00e1ndez-S\u00e1nchez M, Martinez Zurita A, et al. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies. Cancer Cell. 2019;36:369\u2013384.e13.","journal-title":"Cancer Cell"},{"key":"1879_CR21","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Glytsou C, Zhou H, Narang S, Reyna DE, Lopez A, et al. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Disco. 2019;9:890\u2013909.","journal-title":"Cancer Disco"},{"key":"1879_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02867-2","volume":"11","author":"A Roca-Portoles","year":"2020","unstructured":"Roca-Portoles A, Rodriguez-Blanco G, Sumpton D, Cloix C, Mullin M, Mackay GM, et al. Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition. Cell Death Dis. 2020;11:616.","journal-title":"Cell Death Dis"},{"key":"1879_CR23","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1083\/jcb.200908036","volume":"187","author":"X Wang","year":"2009","unstructured":"Wang X, Herr RA, Rabelink M, Hoeben RC, Wiertz EJ, Hansen TH. Ube2j2 ubiquitinates hydroxylated amino acids on ER-associated degradation substrates. J Cell Biol. 2009;187:655\u201368.","journal-title":"J Cell Biol"},{"key":"1879_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/srep16793","volume":"5","author":"AJ Middleton","year":"2015","unstructured":"Middleton AJ, Day CL. The molecular basis of lysine 48 ubiquitin chain synthesis by Ube2K. Sci Rep. 2015;5:16793.","journal-title":"Sci Rep"},{"key":"1879_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-biochem-060815-014922","volume":"86","author":"N Zheng","year":"2017","unstructured":"Zheng N, Shabek N. Ubiquitin ligases: structure, function, and regulation. Annu Rev Biochem. 2017;86:129\u201357.","journal-title":"Annu Rev Biochem"},{"key":"1879_CR26","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1038\/sj.emboj.7601249","volume":"25","author":"R Yonashiro","year":"2006","unstructured":"Yonashiro R, Ishido S, Kyo S, Fukuda T, Goto E, Matsuki Y, et al. A novel mitochondrial ubiquitin ligase plays a critical role in mitochondrial dynamics. EMBO J. 2006;25:3618\u201326.","journal-title":"EMBO J"},{"key":"1879_CR27","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1021\/ml5001867","volume":"5","author":"ZF Tao","year":"2014","unstructured":"Tao ZF, Hasvold L, Wang L, Wang X, Petros AM, Park CH, et al. Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med Chem Lett. 2014;5:1088\u201393.","journal-title":"ACS Med Chem Lett"},{"key":"1879_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","volume":"14","author":"B Nabet","year":"2018","unstructured":"Nabet B, Roberts JM, Buckley DL, Paulk J, Dastjerdi S, Yang A, et al. The dTAG system for immediate and target-specific protein degradation. Nat Chem Biol. 2018;14:431\u201341.","journal-title":"Nat Chem Biol"},{"key":"1879_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18377-w","volume":"11","author":"B Nabet","year":"2020","unstructured":"Nabet B, Ferguson FM, Seong BKA, Kuljanin M, Leggett AL, Mohardt ML, et al. Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nat Commun. 2020;11:4687.","journal-title":"Nat Commun"},{"key":"1879_CR30","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/s41418-020-0503-6","volume":"27","author":"MD Haschka","year":"2020","unstructured":"Haschka MD, Karbon G, Soratroi C, O\u2019Neill KL, Luo X, Villunger A. MARCH5-dependent degradation of MCL1\/NOXA complexes defines susceptibility to antimitotic drug treatment. Cell Death Differ. 2020;27:2297\u2013312.","journal-title":"Cell Death Differ"},{"key":"1879_CR31","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1038\/s41418-020-0517-0","volume":"27","author":"TM Djajawi","year":"2020","unstructured":"Djajawi TM, Liu L, Gong JN, Huang AS, Luo MJ, Xu Z, et al. MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex. Cell Death Differ. 2020;27:2484\u201399.","journal-title":"Cell Death Differ"},{"key":"1879_CR32","doi-asserted-by":"crossref","unstructured":"Arai S, Varkaris A, Nouri M, Chen S, Xie L, Balk SP. MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation. Elife. 2020;9:e54954.","DOI":"10.7554\/eLife.54954"},{"key":"1879_CR33","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/embor.2009.192","volume":"10","author":"R Hjerpe","year":"2009","unstructured":"Hjerpe R, Aillet F, Lopitz-Otsoa F, Lang V, England P, Rodriguez MS. Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep. 2009;10:1250\u20138.","journal-title":"EMBO Rep"},{"key":"1879_CR34","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1233606","volume":"341","author":"D Martinez Molina","year":"2013","unstructured":"Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Dan C, et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science. 2013;341:84\u201387.","journal-title":"Science"},{"key":"1879_CR35","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1101\/gad.1304105","volume":"19","author":"SN Willis","year":"2005","unstructured":"Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005;19:1294\u2013305.","journal-title":"Genes Dev"},{"key":"1879_CR36","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1016\/S2352-3026(22)00076-X","volume":"9","author":"CA Lachowiez","year":"2022","unstructured":"Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, et al. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022;9:e350\u2013e360.","journal-title":"Lancet Haematol"},{"key":"1879_CR37","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov. 2021;11:1440\u201353.","journal-title":"Cancer Discov"},{"key":"1879_CR38","doi-asserted-by":"crossref","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, et al. Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia. J Clin Oncol. 2022;40:4048\u201359.","DOI":"10.1200\/JCO.22.00602"},{"key":"1879_CR39","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","volume":"9","author":"T Nechiporuk","year":"2019","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D\u2019Alessandro A, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019;9:910\u201325.","journal-title":"Cancer Discov"},{"key":"1879_CR40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","volume":"9","author":"P Blombery","year":"2019","unstructured":"Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, et al. Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discov. 2019;9:342\u201353.","journal-title":"Cancer Discov"},{"key":"1879_CR41","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","volume":"10","author":"S Pei","year":"2020","unstructured":"Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, et al. Monocytic subclones confer resistance to venetoclax-based therapy in acute myeloid leukemia patients. Cancer Discov. 2020;10:536\u201351.","journal-title":"Cancer Discov"},{"key":"1879_CR42","doi-asserted-by":"crossref","unstructured":"Blombery P, Lew TE, Dengler MA, Thompson ER, Lin VS, Chen X, et al. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blood. 2021;139:1198\u2013207.","DOI":"10.1182\/blood.2021012775"},{"key":"1879_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41375-019-0485-x","volume":"34","author":"R Bisaillon","year":"2020","unstructured":"Bisaillon R, Moison C, Thiollier C, Krosl J, Bordeleau ME, Lehnertz B, et al. Genetic characterization of ABT-199 sensitivity in human AML. Leukemia. 2020;34:63\u201374.","journal-title":"Leukemia"},{"key":"1879_CR44","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","volume":"1","author":"H Zhang","year":"2020","unstructured":"Zhang H, Nakauchi Y, Kohnke T, Stafford M, Bottomly D, Thomas R, et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020;1:826\u201339.","journal-title":"Nat Cancer"},{"key":"1879_CR45","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020;135:791\u2013803.","journal-title":"Blood"},{"key":"1879_CR46","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1101\/gad.182980.111","volume":"26","author":"SP Glaser","year":"2012","unstructured":"Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012;26:120\u20135.","journal-title":"Genes Dev"},{"key":"1879_CR47","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood.2020010167","volume":"137","author":"R Thijssen","year":"2021","unstructured":"Thijssen R, Diepstraten ST, Moujalled D, Chew E, Flensburg C, Shi MX, et al. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood. 2021;137:2721\u201335.","journal-title":"Blood"},{"key":"1879_CR48","doi-asserted-by":"publisher","first-page":"15986","DOI":"10.18632\/oncotarget.7558","volume":"7","author":"A Subramanian","year":"2016","unstructured":"Subramanian A, Andronache A, Li YC, Wade M. Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA. Oncotarget. 2016;7:15986\u20136002.","journal-title":"Oncotarget"},{"key":"1879_CR49","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","volume":"26","author":"S Jin","year":"2020","unstructured":"Jin S, Cojocari D, Purkal JJ, Popovic R, Talaty NN, Xiao Y, et al. 5-azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis. Clin Cancer Res. 2020;26:3371\u201383.","journal-title":"Clin Cancer Res"},{"key":"1879_CR50","doi-asserted-by":"crossref","unstructured":"Cojocari D, Smith BN, Purkal JJ, Arrate MP, Huska JD, Xiao Y, et al. Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia. Haematologica. 2021;107:825\u201335.","DOI":"10.3324\/haematol.2020.272609"},{"key":"1879_CR51","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1158\/2159-8290.CD-20-1851","volume":"12","author":"S Lin","year":"2022","unstructured":"Lin S, Larrue C, Scheidegger NK, Seong BKA, Dharia NV, Kuljanin M, et al. An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML. Cancer Discov. 2022;12:432\u201349.","journal-title":"Cancer Discov"},{"key":"1879_CR52","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/jb\/mvu016","volume":"155","author":"S Nagashima","year":"2014","unstructured":"Nagashima S, Tokuyama T, Yonashiro R, Inatome R, Yanagi S. Roles of mitochondrial ubiquitin ligase MITOL\/MARCH5 in mitochondrial dynamics and diseases. J Biochem. 2014;155:273\u20139.","journal-title":"J Biochem"},{"key":"1879_CR53","doi-asserted-by":"crossref","unstructured":"Sasaki K, Yamauchi T, Semba Y, Nogami J, Imanaga H, Terasaki T, et al. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL. Blood. 2022;139:748\u201360.","DOI":"10.1182\/blood.2021012976"},{"key":"1879_CR54","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84\u201387.","journal-title":"Science"},{"key":"1879_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0665-3","volume":"11","author":"M Colic","year":"2019","unstructured":"Colic M, Wang G, Zimmermann M, Mascall K, McLaughlin M, Bertolet L, et al. Identifying chemogenetic interactions from CRISPR screens with drugZ. Genome Med. 2019;11:52.","journal-title":"Genome Med"},{"key":"1879_CR56","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cell.2011.02.034","volume":"145","author":"F Edlich","year":"2011","unstructured":"Edlich F, Banerjee S, Suzuki M, Cleland MM, Arnoult D, Wang C, et al. Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Cell. 2011;145:104\u201316.","journal-title":"Cell"},{"key":"1879_CR57","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.molcel.2012.12.022","volume":"49","author":"B Schellenberg","year":"2013","unstructured":"Schellenberg B, Wang P, Keeble JA, Rodriguez-Enriquez R, Walker S, Owens TW, et al. Bax exists in a dynamic equilibrium between the cytosol and mitochondria to control apoptotic priming. Mol Cell. 2013;49:959\u201371.","journal-title":"Mol Cell"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01879-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01879-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01879-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T10:57:11Z","timestamp":1683716231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01879-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1879"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01879-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"11 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}